Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects
November 03 2022 - 1:04PM
Guerbet: Guerbet announces a change in governance for its
Artificial Intelligence projects
Guerbet announces a change in governance
for its Artificial
Intelligence
projects
Villepinte, November
3rd, 2022: Guerbet today announced an
agreement with Merative, formalizing the termination of their
collaboration signed in July 2018.
Guerbet today announced an agreement with
Merative formalizing the termination of their collaboration
initiated in July 2018. This partnership aimed to design, develop
and market software solutions to help diagnose and monitor liver
and prostate cancers. The termination follows Merative's strategic
shift in how it delivers artificial intelligence within its imaging
product portfolio.The new Asset Assignment and License Agreement
grants Guerbet the ability and autonomy to pursue research and
development, and plan for the market launch of Artificial
Intelligence solutions. Assets developed during the partnership,
including source code for application software, Artificial
Intelligence algorithms and the associated intellectual property,
are being transferred to Guerbet.
The market potential remains unchanged and
significant, and this Asset Assignment and License Agreement will
transfer control over the remaining development work to Guerbet.
Promising initial results have been obtained in 2022, particularly
for the detection of liver lesions (presentation scheduled for the
RSNA 2022 conference) and for the detection of prostate cancer
(work presented at the ECR 2022 conference). The high quality of
the work presented by Guerbet’s Artificial Intelligence research
team also impressed the jury of the BPI France 2030 program, which
has awarded the company €1 million in funding for its project aimed
at early detection of pancreatic cancer, as recently announced.
Numerous stakeholders have communicated their
interest to the Group’s management in recent months, attesting to
the business’ strong potential. Constructive discussions are
currently also underway to set up new partnerships in order to
accelerate the business roadmap and to facilitate the emergence of
a national champion in the area of artificial intelligence for
medical imaging.About Guerbet At Guerbet, we build
lasting relationships so that we enable people to live better. That
is our purpose. We are a global leader in medical imaging, offering
a comprehensive range of pharmaceutical products, medical devices,
and digital and AI solutions for diagnostic and interventional
imaging. As pioneers in contrast products for 95 years, with more
than 2,600 employees worldwide, we continuously innovate and devote
8%-10% of our revenue to research and development in five centers
in France, Israel, and the United States. Guerbet (GBT) is listed
on Euronext Paris (segment B – mid caps) and generated €732 million
in revenue in 2021. For more information, please
visit www.guerbet.com
Contact
Claire
Lauvernier, Directrice de la Communication +33.6.79.52.11.88 /
claire.lauvernier@guerbet. 01 45 91 50 00 |
|
- Guerbet CP MERATIVE 2022 VA
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Aug 2023 to Aug 2024